Skip to main content
Premium Trial:

Request an Annual Quote

Talking Drug Development

At R&D Directions Insider, Michael Christel speaks with Bert Spilker, who has worked at a variety of drug companies and has written books on drug development, about mergers and acquisitions, clinical trial reform, transparency, and more. "The issue of transparency has been focused on the industry, and during the '90s and early part of this decade, the industry fought this quite strongly," Spilker says, adding that industry's position has changed. "Today, the industry has accepted the concept of trial registries and is also providing at least a summary of the results of trials on company websites or in a more centralized way."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.